VALNEVA (EPA:VLA) | WebDisclosure

Basculer en Français

9480	Companies
185558	Keywords
117947	Articles
99388	Press releases

Home
Companies
VALNEVA

PRESS RELEASE

published on 04/26/2025 at 19:10, 7 months 9 days ago

Valneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French Authorities
Valneva SE provides an update on the recommendation for the use of its Chikungunya vaccine by French authorities, focusing on adverse events in elderly people. The company is collaborating with regulators on next steps

Valneva SE Chikungunya Vaccine French Authorities Adverse Events Elderly
PRESS RELEASE

published on 04/26/2025 at 19:10, 7 months 9 days ago

Valneva fait un point sur la recommandation d’utilisation de son vaccin contre le chikungunya par les autorités françaises
Valneva met à jour la recommandation d'utilisation de son vaccin IXCHIQ® contre le chikungunya en France suite à des effets indésirables chez les personnes âgées avec comorbidités. Valneva collabore avec les autorités pour assurer la sécurité

Valneva Vaccin Chikungunya Autorités Sanitaires Effets Indésirables
BRIEF

published on 04/18/2025 at 10:05, 7 months 17 days ago

Valneva met à jour sa recommandation concernant le vaccin contre le chikungunya aux États-Unis

Valneva Voyageurs Américains Vaccin Contre Le Chikungunya IXCHIQ® Recommandation De L'ACIP
BRIEF

published on 04/18/2025 at 10:05, 7 months 17 days ago

Valneva Updates on Chikungunya Vaccine Recommendation in the U.S.

Valneva Chikungunya Vaccine IXCHIQ® ACIP Recommendation U.S. Travelers
PRESS RELEASE

published on 04/18/2025 at 10:00, 7 months 17 days ago

Valneva fait le point sur la recommandation de l'ACIP pour les voyageurs américains concernant son vaccin IXCHIQ® contre le chikungunya
Valneva fait le point sur la recommandation de l'ACIP pour les voyageurs américains concernant son vaccin IXCHIQ® contre le chikungunya

Valneva Vaccin Chikungunya IXCHIQ® ACIP
PRESS RELEASE

published on 04/18/2025 at 10:00, 7 months 17 days ago

Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers
Valneva provides update on ACIP recommendation for its chikungunya vaccine IXCHIQ® among U.S. travelers, highlighting new precaution for persons aged 65 years and ongoing safety monitoring

Valneva CDC Chikungunya Vaccine IXCHIQ® ACIP Recommendation
BRIEF

published on 04/09/2025 at 07:05, 7 months 26 days ago

Vaccination du premier enfant dans l'étude de Phase 2 sur le vaccin S4V2 contre la shigellose

Valneva Phase 2 Shigellose Vaccin S4V2 Essai Pédiatrique
BRIEF

published on 04/09/2025 at 07:05, 7 months 26 days ago

First child vaccinated in Phase 2 study of S4V2 shigellosis vaccine

Valneva Phase 2 Shigellosis S4V2 Vaccine Pediatric Trial
PRESS RELEASE

published on 04/09/2025 at 07:00, 7 months 26 days ago

Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2
Valneva and LimmaTech announce first vaccination in Phase 2 infant study of tetravalent Shigella vaccine candidate S4V2. Study aims to combat shigellosis, a deadly diarrheal disease

Valneva Phase 2 Study Shigella Vaccine Shigellosis LimmaTech
PRESS RELEASE

published on 04/09/2025 at 07:00, 7 months 26 days ago

Valneva et LimmaTech annoncent la vaccination du premier participant à l’étude pédiatrique de Phase 2 du candidat vaccin tétravalent contre la shigellose S4V2
Valneva et LimmaTech annoncent la vaccination du premier participant à l’étude pédiatrique de Phase 2 du candidat vaccin tétravalent contre la shigellose S4V2

Valneva Vaccin Shigellose LimmaTech Étude Pédiatrique

Accesswire

Published on 12/05/2025 at 21:45, 21 minutes ago

When the Architecture Becomes Visible: The SMX Revaluation Explained
Published on 12/05/2025 at 21:30, 36 minutes ago

The Identity Layer Beneath Everything: Why Markets Are Revaluing SMX All at Once
Published on 12/05/2025 at 21:20, 46 minutes ago

Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement
Published on 12/05/2025 at 21:00, 1 hour 6 minutes ago

The Repricing Event: Why Multiple Global Industries Are Suddenly Moving Toward SMX
Published on 12/05/2025 at 20:25, 1 hour 41 minutes ago

The Feedback Loop: Why SMX's Adoption in One Industry Accelerates Interest in All the Others

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 18:58, 3 hours 7 minutes ago

EQS-Adhoc: HORNBACH Holding AG & Co. KGaA: Reduced earnings in Q3 2025/26 – Guidance for adjusted EBIT at previous year’s level still valid
Published on 12/05/2025 at 18:26, 3 hours 39 minutes ago

POS-Transaction in Own Shares
Published on 12/05/2025 at 18:15, 3 hours 50 minutes ago

Completion of merger to form Helvetia Baloise Holding Ltd
Published on 12/05/2025 at 17:51, 4 hours 14 minutes ago

Issue of Equity
Published on 12/05/2025 at 17:46, 4 hours 19 minutes ago

Booster Precision Components Holding GmbH announces the successful completion of its Written Procedure to amend and waive certain terms under the terms and conditions of the Bonds

Les Echos

Published on 12/05/2025 at 17:18, 4 hours 47 minutes ago

La vidéo de la réunion de présentation des résultats 2024-2025 du 5 décembre 2025 est disponible
Published on 12/05/2025 at 17:18, 4 hours 47 minutes ago

The video of the 2024-2025 results presentation meeting on December 5, 2025, is available
Published on 12/05/2025 at 15:10, 6 hours 55 minutes ago

Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 15:10, 6 hours 55 minutes ago

Mersen : nombre d'actions et de droits de vote au 30 novembre 2025
Published on 12/05/2025 at 13:58, 8 hours 7 minutes ago

RELATIF A LA MISE A DISPOSITION DU PUBLIC DE LA NOTE D'INFORMATION ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES, NOTAMMENT JURIDIQUES, FINANCIERES ET COMPTABLES DE LEGRAND FRANCE

View all LES ECHOS COMFI WIRE